Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diosmin and Hesperidin in H. pylori Infection
NCT06546111Phase 2
Key facts
- Status
- Recruiting
- Start
- Oct 2024
- Primary completion
- Oct 2025
- Countries
- 1
- Sponsor
- Sadat City University
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Drugs
- diosmin
- Conditions
- Helicobacter pylori infection
01
Overview
Phase 2, randomised, double-blind trial in Helicobacter pylori infection comparing Placebo Group with Daflon Group (2 arms). Primary endpoint: Eradication rate of helicobacter pylori infection at 6 weeks. Started Oct 2024; status: recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Placebo Group
Standard Triple Therapy + Placebo
Daflon Group
Standard Triple Therapy + Daflon
03
Who it enrols
Adult patients (18-75) with confirmed H. pylori infection who have not received prior eradication therapy. Excludes patients with severe comorbidities, GI surgery, or recent use of interacting medications.
04
Endpoints
Primary
Eradication rate of helicobacter pylori infection
Secondary
Tumor Necrosis Factor-Alpha
Malondialdehyde
Beyond the preview
Go deeper on NCT06546111.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06546111.